Free Trial

Insmed (INSM) Stock Price, News & Analysis

Insmed logo
$100.64 +1.15 (+1.16%)
As of 06/30/2025 04:00 PM Eastern

About Insmed Stock (NASDAQ:INSM)

Key Stats

Today's Range
$99.78
$101.64
50-Day Range
$65.08
$105.90
52-Week Range
$60.40
$106.83
Volume
4.23 million shs
Average Volume
2.30 million shs
Market Capitalization
$19.09 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$106.80
Consensus Rating
Buy

Company Overview

Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical company dedicated to developing and commercializing therapies for patients with serious and rare diseases. The company’s expertise lies in inhaled and systemic drug-delivery technologies designed to target diseases with high unmet medical needs. Insmed’s lead product, Arikayce® (amikacin liposome inhalation suspension), is the first and only FDA-approved therapy for refractory Mycobacterium avium complex (MAC) lung disease in adults, representing a significant advance in treating this life-threatening pulmonary condition.

Arikayce, administered via nebulizer, employs liposomal encapsulation to deliver high concentrations of antibiotic directly to the site of infection while minimizing systemic exposure. Initially approved in the United States, the product has since received marketing authorizations in Europe, Canada, Japan and Australia, establishing Insmed’s footprint in key global markets. The company works closely with pulmonologists, infectious disease specialists and patient advocacy groups to support disease awareness, diagnosis and access to therapy.

Beyond Arikayce, Insmed maintains a growing pipeline of investigational therapies targeting serious rare diseases in pulmonology, nephrology and genetic disorders. Its research programs leverage proprietary delivery platforms and robust preclinical models to advance novel candidates toward regulatory milestones. Collaborations with academic institutions and industry partners further enhance Insmed’s ability to expand its portfolio and address additional high-impact indications.

Founded in 2005 and headquartered in Bridgewater, New Jersey, Insmed operates research, development and commercial teams across the United States and Europe. Under the leadership of President and Chief Executive Officer Will Lewis, the company emphasizes patient-centric innovation, rigorous clinical science and strategic regulatory planning. Insmed’s global organization continues to grow, fostering a network of experts committed to improving outcomes for patients affected by rare and serious diseases.

AI Generated. May Contain Errors.

Insmed Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
82nd Percentile Overall Score

INSM MarketRank™: 

Insmed scored higher than 82% of companies evaluated by MarketBeat, and ranked 202nd out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Insmed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 17 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Insmed has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Insmed's stock forecast and price target.
  • Earnings Growth

    Earnings for Insmed are expected to grow in the coming year, from ($4.56) to ($2.89) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Insmed is -16.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Insmed is -16.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Insmed has a P/B Ratio of 62.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Insmed's valuation and earnings.
  • Percentage of Shares Shorted

    6.33% of the float of Insmed has been sold short.
  • Short Interest Ratio / Days to Cover

    Insmed has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Insmed has recently decreased by 33.28%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Insmed does not currently pay a dividend.

  • Dividend Growth

    Insmed does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.33% of the float of Insmed has been sold short.
  • Short Interest Ratio / Days to Cover

    Insmed has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Insmed has recently decreased by 33.28%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Insmed has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Insmed this week, compared to 12 articles on an average week.
  • Search Interest

    22 people have searched for INSM on MarketBeat in the last 30 days. This is an increase of 633% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added Insmed to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Insmed insiders have sold 21,318.50% more of their company's stock than they have bought. Specifically, they have bought $201,694.00 in company stock and sold $43,199,826.00 in company stock.

  • Percentage Held by Insiders

    Only 3.00% of the stock of Insmed is held by insiders.

  • Read more about Insmed's insider trading history.
Receive INSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insmed and its competitors with MarketBeat's FREE daily newsletter.

INSM Stock News Headlines

An investor analyzing the russell 1000 etf fund on a screen. A phone shows the prices of Russell 1000 — Stock Editorial Photography
Russell Rebalance: 3 Stocks Ready to Move Higher (INSM)
The Russell reconstitution is underway; here are three stocks that are garnering interest as stocks that could move up to the Russell 1000...
How to Collect Up To $5,917/mo From Trump’s Made In USA Boom
How to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First policies, a historic wave of investment is flooding back into the United States: Apple committing a colossal $500 billion to build new U.S. factories. Microsoft injecting $80 billion into domestic manufacturing. Nvidia moving critical chip production back to America. But here's the hidden opportunity: There's now a groundbreaking way for you to start collecting monthly checks from these very same companies— checks that could reach as high as $5,917 each month. Don't miss your chance to participate directly in America's industrial comeback.
6INSM : What Does the Market Think About Insmed?
See More Headlines

INSM Stock Analysis - Frequently Asked Questions

Insmed's stock was trading at $69.04 at the start of the year. Since then, INSM shares have increased by 45.8% and is now trading at $100.64.
View the best growth stocks for 2025 here
.

Insmed, Inc. (NASDAQ:INSM) posted its quarterly earnings data on Thursday, May, 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing analysts' consensus estimates of ($1.36) by $0.06. Insmed's quarterly revenue was up 22.9% compared to the same quarter last year.
Read the conference call transcript
.

Shares of INSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Insmed investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), CrowdStrike (CRWD), Advanced Micro Devices (AMD) and Arista Networks (ANET).

Company Calendar

Last Earnings
5/08/2025
Today
7/01/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:INSM
Employees
1,271
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$106.80
High Stock Price Target
$120.00
Low Stock Price Target
$92.00
Potential Upside/Downside
+6.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
17 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$913.77 million
Net Margins
-265.93%
Pretax Margin
-264.87%

Debt

Sales & Book Value

Annual Sales
$363.71 million
Price / Cash Flow
N/A
Book Value
$1.60 per share
Price / Book
62.90

Miscellaneous

Free Float
184,022,000
Market Cap
$19.09 billion
Optionable
Optionable
Beta
0.80

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:INSM) was last updated on 7/1/2025 by MarketBeat.com Staff
From Our Partners